Quarterly Financial Data (Unaudited and restated) - Restated consolidated statements of operations and comprehensive loss (Details) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Income tax benefit	$ (37,063)	$ 3,326,000	$ 3,326,000	$ 3,288,937	$ 3,288,937	$ 145,974
Net loss	(13,347,771)	(6,937,910)	(15,127,708)	(28,475,479)	(43,862,197)	(35,400,807)
Net loss attributable to NightHawk Biosciences, Inc.	$ (13,258,350)	$ (6,831,286)	$ (14,951,873)	$ (28,210,223)	$ (43,434,706)	$ (35,071,468)
Net loss per share, basic (in dollars per share)	$ (0.52)	$ (0.27)	$ (0.58)	$ (1.10)	$ (1.70)	$ (1.41)
Net loss per share, diluted (in dollars per share)	$ (0.52)	$ (0.27)	$ (0.58)	$ (1.10)	$ (1.70)	$ (1.41)
Total comprehensive loss	$ (13,232,112)	$ (6,788,055)	$ (15,033,122)	$ (28,265,234)	$ (43,742,332)	$ (35,302,692)
Comprehensive loss - NightHawk Biosciences, Inc.	(13,142,691)	(6,681,431)	(14,857,287)	(27,999,978)	$ (43,314,841)	$ (34,973,353)
As Previously Reported
Income tax benefit	215,937			215,937
Net loss	(13,094,771)	(10,263,910)	(18,453,708)	(31,548,479)
Net loss attributable to NightHawk Biosciences, Inc.	$ (13,005,350)	$ (10,157,286)	$ (18,277,873)	$ (31,283,223)
Net loss per share, basic (in dollars per share)	$ (0.51)	$ (0.40)	$ (0.71)	$ (1.22)
Net loss per share, diluted (in dollars per share)	$ (0.51)	$ (0.40)	$ (0.71)	$ (1.22)
Total comprehensive loss	$ (12,979,112)	$ (10,114,055)	$ (18,359,122)	$ (31,338,234)
Comprehensive loss - NightHawk Biosciences, Inc.	(12,889,691)	(10,007,431)	(18,183,287)	(31,072,978)
Adjustments
Income tax benefit	(253,000)	3,326,000	3,326,000	3,073,000
Net loss	(253,000)	3,326,000	3,326,000	3,073,000
Net loss attributable to NightHawk Biosciences, Inc.	$ (253,000)	$ 3,326,000	$ 3,326,000	$ 3,073,000
Net loss per share, basic (in dollars per share)	$ (0.01)	$ 0.13	$ 0.13	$ 0.12
Net loss per share, diluted (in dollars per share)	$ (0.01)	$ 0.13	$ 0.13	$ 0.12
Total comprehensive loss	$ (253,000)	$ 3,326,000	$ 3,326,000	$ 3,073,000
Comprehensive loss - NightHawk Biosciences, Inc.	$ (253,000)	$ 3,326,000	$ 3,326,000	$ 3,073,000